Raymond W. Cohen, CEO of Symphony Medical, has more than 25 years of leadership and entrepreneurial experience in health care. He was for the past nine years the CEO of publicly-held Cardiac Science, Inc., a leading U.S. manufacturer of life-saving automatic public-access defibrillators that merged with Bothell, WA-based Quinton Cardiology Systems Inc. in 2005 and operates today under the name Cardiac Science Corporation, (Nasdaq: CSCX), where Cohen remains chairman of the board of directors. Cohen also serves as a member of the board of directors of BioLife Solutions, Inc, (Nasdaq OTC: BLFS.OB), a manufacturer of cryopreservation products used for human cell and tissue preservation, based in Owego, NY; and Syncroness, Inc., a privately-held contract engineering and product development firm based in Westminster, CO. He is also a member of the Advisory Board for the College of Osteopathic Medicine, Western University of Health Sciences in Pomona, CA.

When Cohen joined Cardiac Science in 1997 as its CEO, that company had no commercial products or revenue and only one issued patent. By 2004, under Cohen's leadership, it had grown to over $68 million in annual revenue, amassed an intellectual property portfolio of 77 issued patents and was ranked as the fourth fastest growing technology company in North America on the Deloitte & Touche Fast 500 list. In 2003, Cardiac Science was named Life Science Company of the Year by the American Electronics Association and Entrepreneurial Company of the Year by Frost and Sullivan in 2004.

Cohen is a graduate of State University of New York at Binghamton with a degree in business management and is an accredited public-company director having completed the certification program at UCLA’s Anderson Graduate School of Management.

Frank Ahmann, Chief Operating Officer of Symphony Medical, Inc., is a healthcare entrepreneur with nineteen years of experience in developing and commercializing biopharmaceutical products and medical devices. Prior to joining Symphony, Frank was COO of Nephrogenex, Inc., an early stage company applying molecular profiling technologies to develop new therapies for kidney disease; President and CEO of Allvivo, Inc., a company marketing bioreactive surface coatings for medical devices; and COO of Chimeric Therapies, Inc., a developer of stem cell therapeutics to induce immune tolerance in transplant patients. He was also a strategy consultant to various biotechnology start-up ventures in the cardiovascular and oncology sectors. Before his involvement with healthcare start-ups, Frank worked for Baxter International where he held management positions in various areas of increasing responsibility. Directing an international group responsible for building the company's immunotherapy and stem cell transplantation businesses, he spent eight years in Europe before relocating to Southern California to create and manage a new vascular business unit at the company's Cardiovascular Group (now Edwards Lifesciences). From early research stages, Frank has brought to market numerous successful biologics and devices in the areas of hematology, oncology, transplantation medicine, and cardiovascular surgery. He holds a BBA from the University of Texas at Austin and an MBA from Columbia University's Graduate Business School in New York City.

Andy G. Hinson directs the clinical and regulatory activities at Symphony Medical. Andy has 15 years of bio-pharmaceutical industry experience and 20 years of experience spanning clinical and R&D assignments in the cardiovascular arena. Prior to joining Symphony Medical in November 2004, Andy was Senior Director of Research & Development at AnGes Inc, a successful Japanese biotechnology start-up that is developing novel gene based approaches for the treatment of cardiovascular disease. During Andy's tenure at AnGes, the company successfully filed IND's in the US and Japan and advanced combinations of device and biologics into early and late stage clinical programs. These clinical development programs included the first human studies ever performed for the gene transfer of hepatocyte growth factor and NFKB (nuclear factor kappa B) decoy, as the company transitioned from a start-up venture to a publicly traded company on the Tokyo Stock Exchange of nearly 100 employees. Before that, Andy was a Senior Manager in the Medical Affairs & Clinical Development Cardiovascular Division at Procter & Gamble Pharmaceutical. Andy's long tenure at P&GP included a variety of research and development responsibilities spanning arrhythmia, heart failure, hypertension and myocardial injury programs. Andy's early career began as a cardiovascular technologist and applications consultant to the medical device industry.

Sam L. Helgerson directs the research and development activities at Symphony Medical. Sam has 16 years experience in the biotechnology industry. Prior to joining Symphony Medical in July 2007, Sam was a Senior R&D Director with the BioSurgery Group of the Baxter Healthcare’s BioScience Division. Sam directed R&D activities focused on developing bio-therapeutic products for tissue regeneration, especially to promote angiogenesis and revascularization in both wound healing and cardiovascular disease applications. This work included developing patented technology for therapeutic delivery of growth and angiogenic factors using biopolymers as delivery matrices for novel engineering recombinant proteins. Sam joined Baxter in 1991 and has extensive R&D and process development experience with blood plasma-derived protein, monoclonal antibody, and recombinant protein biopharmaceutical products. These products were developed under both FDA and European regulatory guidelines for Biologics, Medical Devices, or Combined Medical Device filings. Before that, Sam held academic research positions as an Adjunct Professor of Chemistry at Montana State University, an Assistant Research Biophysicist at the UCSF Cardiovascular Research Institute, and a National Research Council Associate at the NASA Ames Research Center. Sam hold a Ph.D. Degree in Biophysics from Purdue University and a B.S. Degree in Physics from the University of Puget Sound. Sam is a member of numerous professional scientific organizations including the American Heart Association, the American Society for Cell Biology, the International Society for Thrombosis and Haemostasis, and the Society for Vascular Medicine and Biology.

Norman Tarazona directs the preclinical research and development activities at Symphony Medical, Inc. Norman has 17 years experience in cardiovascular preclinical research both on the academic and industry aspects. Prior to joining Symphony Medical in February 2006, Norman was Director of Preclinical Research at Conor Medsystems, Inc, a drug eluting coronary stent company in Northern California. During his time there, he was responsible for the development of new preclinical research programs as well as being directly involved in the filings with the different regulatory entities in order to advance Conor technologies to the clinical research programs and the subsequent entry into the market. Before this, Norman was Director of Veterinary Sciences at GMP Companies, Inc. in Atlanta, GA. Coming on as the 5^th employee of this start-up company and during his 5 year stay, he was responsible with starting a preclinical research program from scratch in various areas including: coronary stents, wireless EKG and implantable ocular devices for the treatment of glaucoma. Prior to his entry into the industry aspect of research, he began his career working for 9 years in academia developing new devices and treatments for angioplasty and restenosis. He began at Emory University and then received faculty appointments at the medical schools of Temple University in Philadelphia and Cornell University in New York. Norman obtained his DVM from La Salle University (Bogota, Colombia).

Rena Juliar, Director of Product Development for Symphony Medical, Inc., has 20 years experience bringing new medical devices and technologies from the research phase into the commercial market. Prior to joining Symphony, Rena was Director of Manufacturing and Technology at IDM Pharma, a biopharmaceutical company focused on the development of innovative oncology products that activate the immune system. These products include both classical pharmaceuticals and autologous cell therapies. During Rena's tenure, the company initiated United States clinical trials with autologous cell products prepared using proprietary manufacturing technology in the company's licensed facility. Previously, Rena was Director of Development for Nexell Therapeutics (formerly Baxter Immunotherapy) where she led medical device development for oncology products focused on transplant therapies. Before that, Rena developed various medical products in the cardiopulmonary arena for Medtronic and Baxter's Bentley division. Rena holds a degree in Bioengineering from the University of California at San Diego.

Bob Peterson, Director of Research, is a product development executive with over 20 years in the biopharmaceutical and medical implants industries. Prior to joining Symphony Medical, for eight years, Bob was Director of Biopharmaceutical Drug Development for Biostratum, Inc., where he oversaw the development of therapeutic antibodies and recombinant proteins with applications in oncology, angiogenesis, tissue engineering, and cell therapies. He managed key collaboration programs with major academic research centers and international corporate partners. Before Biostratum, Bob was a Director of R&D at Baxter International´s CardioVascular Group (now Edwards Lifesciences). At Baxter, Bob spearheaded from concept to market release the development of endovascular grafts for Abdominal Aortic Aneurysms as well as a line of ePTFE grafts for vascular and coronary applications. Prior to entering the medical industry, Bob was a Lieutenant of the United States Army. He holds a B.S. in Engineering from the United States Military Academy in West Point and a Masters in Mechanical Engineering from the University of California Berkeley.